Ascendis Pharma A/S Stock News

–– TransCon™ PTH Phase 3 topline results expected in Q1 2022 and, if positive, planned NDA submission in Q3 2022 followed by expected MAA submission in Q4 2022 –– Enrollment completed in Phase 2 ACcomplisH Trial of TransCon CNP; blinded data informed dose selection of 50 and 100 μ g/kg/week in

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been assigned an average rating of Buy from the thirteen brokerages that are currently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price objective among brokerages []

Equities researchers at Wells Fargo & Company began coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a note issued to investors on Wednesday, PriceTargets.com reports. The brokerage set an overweight rating and a $176.00 price target on the biotechnology companys stock. Wells Fargo & Companys target price indicates a potential upside of 26.03% from []

Parametric Portfolio Associates LLC increased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 38.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,565 shares of the biotechnology companys stock after buying an additional 7,620 shares during the quarter. Parametric []

COPENHAGEN, Denmark, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will host a virtual R&D Program Update for the investment community on Tues

COPENHAGEN, Denmark , Dec. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will host a virtual R&D Program Update for the investment community on Tuesday, December 14, 2021 . The event will feature updates on Ascendis Pharmas endocrinology rare

Wall Street analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to announce $4.34 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Ascendis Pharma A/Ss earnings, with estimates ranging from $930,000.00 to $9.63 million. Ascendis Pharma A/S posted sales of $640,000.00 in the same quarter last year, []

Equities analysts forecast that Ascendis Pharma A/S (NASDAQ:ASND) will announce earnings of ($2.65) per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Ascendis Pharma A/Ss earnings. The highest EPS estimate is ($2.16) and the lowest is ($3.05). Ascendis Pharma A/S posted earnings of ($3.15) per share in the []

Ascendis Pharma A/S (NASDAQ:ASND) concluded the trading at $135.61 on Friday, December 03 with a fall of -7.05% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $145.89 and 5Y monthly beta was reading 0.79 with its price kept floating in the Ascendis Pharma A/S (ASND) Worth Considering For The Next Few Weeks Read More »

Ascendis Pharma A/S (NASDAQ:ASND) and Sol-Gel Technologies (NASDAQ:SLGL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings. Profitability This table compares Ascendis Pharma A/S and Sol-Gel Technologies net margins, return on equity [] The post Head to Head Contrast: Ascendis Pharma A/S (NASDAQ:ASND) versus Sol-Gel Technologies (NASDAQ:SLGL) appeared first on ETF Daily News .

HOUSTON and SINGAPORE , Nov. 29, 2021 /PRNewswire/ -- Hummingbird Bioscience Holdings Limited, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announced the appointment of Jan Møller Mikkelsen as Chairman of its Board of Directors. "I am delighted to welcome Jan to Hummingbird''s Board of Directors as our Chairman. His extensive experience leading and scaling businesses spanning from drug discovery to commercial stage companies is invaluable to Hummingbird Bioscience, as we chart our next stage of growth and pursue our mission of bringing precision medicines to patients," said Piers Ingram , CEO and co-founder of Hummingbird Bioscience. Mr. Mikkelsen currently serves as President, CEO and Board member of Ascendis Pharma, a pharmaceutical company he founded in 2007. He was previously President and CEO of LifeCycle Pharma, President of the Pharmaceutical Division of Maxygen, Inc., as well as co-founder of ProFound Pharma where he also served as co-CEO.

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have earned an average recommendation of Buy from the twelve ratings firms that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1 year target price among []

Infill and extension drilling intended to upgrade, expand and improve grade of the existing resource Infill and extension drilling intended to upgrade, expand and improve grade of the existing resourc

Senior mining finance & M&A professional to augment growth opportunities Senior mining finance & M&A professional to augment growth opportunities

Cantor Fitzgerald reaffirmed their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report released on Thursday morning, Zacks.com reports. ASND has been the subject of a number of other research reports. Credit Suisse Group cut their target price on shares of Ascendis Pharma A/S from $185.00 to $179.00 and set an []